Oxford Eye Hospital, John Radcliffe Hospital, Headley Way, Oxford, UK.
Retina. 2010 Oct;30(9):1400-4. doi: 10.1097/IAE.0b013e3181d374dc.
The purpose of the study was to report the use of ranibizumab in choroidal neovascularization secondary to punctate inner choroidopathy.
This was a retrospective case series. Clinical notes of 10 patients with choroidal neovascularization secondary to punctate inner choroidopathy were reviewed (mean age, 40.7 years, age range, 25-58 years).
Previous therapies included photodynamic therapy, posterior sub-Tenon's triamcinolone, oral prednisolone, and intravitreal triamcinolone. Ten eyes in 10 patients underwent a mean of 1.9 ± 1.3 (± standard deviation) injections of antivascular endothelial growth factor (range, 1-5). All 10 patients had a follow-up review of at least 6 months (median, 12.5 ± 9.2 standard deviation; range, 6-34 months). Nine eyes either maintained or improved vision by at least 1 line on the logarithmic of the minimal angle of resolution calculated equivalent chart at least 6 months after the start of treatment with antivascular endothelial growth factor therapy. No ocular or systemic complications were observed.
The role of ranibizumab in choroidal neovascularization in association with punctate inner choroidopathy has been shown to be beneficial in this small group in whom improvement or stabilization of vision was observed in 9 of 10 eyes. Recurrent choroidal neovascularization can occur in these patients, and additional injections of ranibizumab appear to be safe and efficacious.
本研究旨在报告雷珠单抗在特发性脉络膜新生血管（PCV）中的应用。
这是一项回顾性病例系列研究。回顾了 10 例特发性脉络膜新生血管（PCV）患者（平均年龄 40.7 岁，年龄范围 25-58 岁）的临床资料。
既往治疗包括光动力疗法、后Tenon 下曲安奈德、口服泼尼松龙和玻璃体内曲安奈德。10 例患者的 10 只眼平均接受 1.9±1.3（±标准差）次抗血管内皮生长因子（VEGF）注射（范围 1-5 次）。所有 10 例患者的随访时间至少为 6 个月（中位数 12.5±9.2 标准差；范围 6-34 个月）。在开始抗 VEGF 治疗后至少 6 个月，9 只眼的对数最小角分辨率计算等效图表上的视力至少提高或稳定了 1 行，9 只眼中有 10 只眼的视力得到了改善。未观察到眼部或全身并发症。
在本小样本研究中，雷珠单抗在特发性脉络膜新生血管（PCV）中的应用是有益的，10 只眼中有 9 只眼的视力得到了改善或稳定。这些患者可能会出现脉络膜新生血管复发，额外注射雷珠单抗似乎是安全有效的。
